{
    "case_id": "MN23-40548",
    "year": 2023,
    "patient_info": {
        "age_range": "51 to 64",
        "gender": "Female"
    },
    "diagnosis": "Lupus",
    "secondary_conditions": [],
    "complications": [],
    "symptoms": [],
    "treatment_category": "Pharmacy",
    "treatment_subcategory": "Weight Control",
    "treatments_requested": [
        {
            "name": "Wegovy solution auto-injector 2.4 mg/0.75 mL",
            "drug_type": "standard",
            "procedure_type": null,
            "is_procedure": false,
            "other_or_notes": null
        }
    ],
    "treatments_tried_but_failed": [],
    "treatments_tried_and_worked": [],
    "treatments_not_tried": [],
    "is_denial_upheld": true,
    "issues_considered": [
        "medical_necessity",
        "plan_coverage"
    ],
    "other_issues": null,
    "guidelines_support": false,
    "guidelines_not_support": true,
    "guidelines_details": "Current obesity management guidelines do not support further pharmacotherapy for patients with a BMI of 20.48 kg/m2.",
    "soc_support": false,
    "soc_not_support": true,
    "soc_details": "No medical guidance suggests further weight loss or continuation of Wegovy would improve autoimmune-related symptoms.",
    "study_support": true,
    "study_details": [
        {
            "study_name": "Semaglutide Cessation Study",
            "study_authors": "Not specified",
            "key_findings": "Cessation of semaglutide after 20 weeks resulted in an average 6.9% weight increase. No consensus on continuation for non-obese patients."
        }
    ],
    "key_questions": [
        "medical_necessity",
        "plan_coverage"
    ],
    "expedited": true,
    "rationale": "The requested Wegovy solution is not medically necessary as the patient's BMI is 20.48 kg/m2, and current guidelines do not support further pharmacotherapy. The improvement in autoimmune symptoms is attributed to previous weight loss, not the continuation of Wegovy.",
    "reviewer_credentials": "Board-certified in endocrinology, diabetes, and metabolism, actively practicing with expertise in the treatment of the enrolleeâ€™s medical condition."
}